ERBB2 and breast cancer: In HER2-positive breast cancer, less immunosuppressive regimens (e.g., paclitaxel + trastuzumab, trastuzumab emtansine) may be considered as an option over more suppressive regiments (e.g., docetaxel, carboplatin, trastuzumab and pertuzumab) [22–24].